Medtronic's Altaviva Device Revolutionizes Urinary Incontinence Treatment
Medtronic has made a significant stride in urinary incontinence treatment with the FDA approval of its Altaviva device. This innovation makes Medtronic the sole company offering a complete range of neuromodulation therapies for urge urinary incontinence, a condition affecting around 16 million U.S. adults.
The Altaviva device, inserted near the ankle, sends electrical impulses to the tibial nerve, helping regulate bladder control. Unlike other devices, Altaviva is activated upon implantation and doesn't require daily recharging or manual adjustments from the patient. It's designed to last 15 years and is MRI-compatible, providing long-term peace of mind for patients.
Urge urinary incontinence can significantly impact quality of life, mental health, and sleep. However, only a quarter of those affected have discussed their symptoms with a doctor, indicating a need for more treatment options. Medtronic's Altaviva device offers a new solution, potentially improving the lives of many sufferers.
Medtronic's Altaviva device, with its 15-year battery lifespan and MRI compatibility, provides a long-term, minimally invasive solution for urge urinary incontinence. Its FDA approval in the U.S. offers hope to the millions affected, encouraging more open conversations about this condition and its treatment.
Read also:
- EU Faces Demand from Protesters to Halts Incineration of American-Owned Birth Control Products
- MERS (Middle East Respiratory Syndrome): A Comprehensive Overview and Treatment Guide
- Strategies to Maintain Optimal Eye Health Throughout Aging Process
- Hearings on the HHS Budget Detail a Fresh Approach for Public Healthcare Policies
